Trilogy Capital’s DexCom DXCM Stock Holding History

Trilogy Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$400K	Hold	5,945	–	–	0.02%	296
2026 Q1	$373K	Sell	5,945 -803	-12%	-$55.9K	0.02%	294
2025 Q4	$448K	Hold	6,748	–	–	0.02%	257
2025 Q3	$454K	Buy	6,748 +3	+0%	+$237	0.02%	259
2025 Q2	$589K	Buy	6,745 +35	+0.5%	+$2.74K	0.03%	217
2025 Q1	$458K	Hold	6,710	–	–	0.02%	228
2024 Q4	$522K	Sell	6,710 -157	-2%	-$11.6K	0.03%	223
2024 Q3	$460K	Sell	6,867 -9,420	-58%	-$774K	0.02%	230
2024 Q2	$1.85M	Buy	16,287 +12,895	+380%	+$1.63M	0.1%	134
2024 Q1	$470K	Buy	+3,392	New	+$426K	0.03%	204
2018 Q4	–	Sell	-160	Closed	-$6K	–	251
2018 Q3	$6K	Buy	+160	New	+$4.96K	﹤0.01%	372
2018 Q2	–	Sell	-140	Closed	-$3K	–	586
2018 Q1	$3K	Buy	+140	New	+$2.07K	﹤0.01%	346

Other funds holding DXCM

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FFM

Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIAS

Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Trilogy Capital's DXCM Position: Q2 2026 in Review

Trilogy Capital held its DexCom (DXCM) position steady in Q2 2026 at 5,945 shares worth $400K. The position accounts for 0.02% of the portfolio, ranked #296.

Trilogy Capital first reported a position in DXCM in Q1 2018 and has held it in 12 quarters since. The position peaked at $1.85M in Q2 2024. 115 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Trilogy Capital held 5,945 shares of DexCom worth $400K as of Q2 2026.
Trilogy Capital left its DexCom share count unchanged in Q2 2026.
DexCom made up 0.02% of Trilogy Capital's portfolio in Q2 2026, its #296 holding.
Trilogy Capital first reported a position in DexCom in Q1 2018 and has held it in 12 quarters since.
Trilogy Capital's DexCom position peaked at $1.85M in Q2 2024.
115 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.